Novo Nordisk is highlighted as a competitor to Pfizer, benefiting from weight loss treatments, and is being watched by the creator.
Source Post
Is Pfizer an Excellent Dividend Stock to Buy? | PFE Stock Analysis
Sep 17, 2026
The creator analyzes Pfizer (PFE) as a potential dividend stock, noting its use of AI in drug discovery and manufacturing. Despite past revenue volatility, management forecasts high single-digit growth from 2028-2033. The stock's valuation is considered attractive, trading at a forward PE of 9.6, which the creator believes is justified given its performance metrics. A discounted cash flow model suggests significant upside potential.
Linked Mentions
Tickers discussed in this post
Eli Lilly is mentioned as a competitor benefiting from weight loss treatments and is owned by the creator.
Pfizer stock is a buying opportunity with considerable upside of over 80% based on a fair value estimate of $50 per share, significantly above its current market price of $28.
Linked Signals
Tracked calls opened from this post
PFEbuy opened Sep 17, 2026
+7.02%